NEW YORK (GenomeWeb) – NeoGenomics announced today its participation as a designated laboratory in the NCI-Molecular Analysis for Therapy Choice, or NCI-MATCH, precision medicine cancer treatment clinical trial.
As a designated sequencing lab for the trial, the Fort Myers, Florida-based company will use its NeoType Discovery Panel to identify patients who may be eligible for treatment of their tumor types at clinical sites participating in NCI-MATCH. The panel assesses 320 cancer-related genes in solid tumors, hematologic malignancies, and advanced sarcomas.
NeoGenomics will proactively search for tumor gene abnormalities being studied in the trial, and if they are found, the company will notify the ordering physician that the patient may be a candidate for NCI-MATCH.
Launched in 2015, NCI-MATCH is testing the efficacy of cancer treatments that are selected based on the genomic markers driving patients' tumors, regardless of cancer type. Earlier this month, Strata Oncology announced its participation in the trial.
In June, NCI-MATCH investigators reported initial results for three of the study's treatment arms.